Global Biosimilar Monoclonal Antibody Production Market Strategic Research Report

The global biosimilar monoclonal antibody (mAb) production market has emerged as one of the most consequential segments within the broader biopharmaceutical manufacturing landscape. Valued at approximately USD 8.4 billion in 2024, the market encompasses the upstream and downstream processes, cell culture technologies, purification systems, and contract manufacturing services required to produce biosimilar versions of reference monoclonal antibodies whose patents have expired or are approaching expiry. As blockbuster biologics such as adalimumab, bevacizumab, trastuzumab, and rituximab face intensifying biosimilar competition across North America, Europe, and Asia Pacific, the infrastructure required to manufacture these complex proteins at commercial scale has attracted substantial capital investment from both established CDMOs and vertically integrated pharmaceutical manufacturers seeking to diversify revenue streams.

Three principal forces are propelling market expansion. First, the accelerating patent cliff affecting originator biologics — an estimated USD 100 billion in biologic revenues will lose exclusivity between 2024 and 2030 — creates structural demand for biosimilar production capacity at a pace that outstrips current installed infrastructure. Second, favourable regulatory pathways introduced by the FDA's 351(k) biosimilar approval framework and the EMA's mature biosimilar guidelines have compressed development timelines and improved commercial predictability, incentivising manufacturers to commit to large-scale production investments rather than treating biosimilars as speculative pipeline assets. Third, single-use bioreactor technology and continuous bioprocessing platforms have materially reduced the capital expenditure and batch failure risk historically associated with mAb manufacturing, lowering the barrier to entry for emerging-market producers in India, South Korea, and China. The primary restraint on market growth is the analytical complexity of demonstrating biosimilarity for highly glycosylated mAbs, where post-translational modification variability can trigger costly comparability studies or complete market withdrawal.

This report provides a comprehensive analysis of the biosimilar mAb production market across the 2025–2032 forecast period, examining market size by production technology type, end-use therapeutic application, and geography. It profiles ten leading production companies in detail and benchmarks their manufacturing capacity, pipeline depth, and strategic positioning. The report is essential reading for corporate strategy teams evaluating CDMO partnerships, investment analysts assessing capacity expansion capital allocation, and procurement managers negotiating long-term manufacturing agreements.